131 related articles for article (PubMed ID: 31291178)
1. Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?
Tabanor JA; Lakshminarayanan S
Cleve Clin J Med; 2019 Jul; 86(7):449-453. PubMed ID: 31291178
[No Abstract] [Full Text] [Related]
2. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
4. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
5. Infection Risk and Safety of Corticosteroid Use.
Youssef J; Novosad SA; Winthrop KL
Rheum Dis Clin North Am; 2016 Feb; 42(1):157-76, ix-x. PubMed ID: 26611557
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
7. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S
Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999
[TBL] [Abstract][Full Text] [Related]
8. [Pneumocystis pneumonia among patients with systemic diseases].
Khellaf M; Godeau B
Presse Med; 2009 Feb; 38(2):251-9. PubMed ID: 19062243
[TBL] [Abstract][Full Text] [Related]
9. Rapid glucocorticoid tapering therapy to reduce mortality from pneumocystis pneumonia in patients with rheumatic disease.
Ando T; Abe Y; Endo Y; Tada K; Yamaji K; Tamura N
Mod Rheumatol; 2019 Jul; 29(4):656-661. PubMed ID: 29972334
[No Abstract] [Full Text] [Related]
10. A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis.
Cettomai D; Gelber AC; Christopher-Stine L
J Rheumatol; 2010 Apr; 37(4):792-9. PubMed ID: 20194450
[TBL] [Abstract][Full Text] [Related]
11. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations.
Caplan A; Fett N; Rosenbach M; Werth VP; Micheletti RG
J Am Acad Dermatol; 2017 Feb; 76(2):191-198. PubMed ID: 28088990
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant Pneumocystis jirovecii pneumonia--a re-emerged public health problem?
Chapman JR; Marriott DJ; Chen SC; MacDonald PS
Kidney Int; 2013 Aug; 84(2):240-3. PubMed ID: 23739237
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis.
Anand S; Samaniego M; Kaul DR
Transpl Infect Dis; 2011 Dec; 13(6):570-4. PubMed ID: 22093215
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?
Wolfe RM; Peacock JE
Curr Rheumatol Rep; 2017 Jun; 19(6):35. PubMed ID: 28488228
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis.
de Boer MG; Kroon FP; le Cessie S; de Fijter JW; van Dissel JT
Transpl Infect Dis; 2011 Dec; 13(6):559-69. PubMed ID: 21689251
[TBL] [Abstract][Full Text] [Related]
16. [Pneumocystis prophylaxis during glucocorticoid use?].
de Mast Q; Thurlings R; Ten Oever J
Ned Tijdschr Geneeskd; 2018 Aug; 162():. PubMed ID: 30212009
[TBL] [Abstract][Full Text] [Related]
17. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
19. Healthcare related transmission of Pneumocystis pneumonia: From key insights toward comprehensive prevention.
de Boer MGJ; Walzer PD; Mori S
Transpl Infect Dis; 2018 Oct; 20(5):e12942. PubMed ID: 29873156
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic Infections in Biological Therapy, Risk and Prevention.
Bryant PA; Baddley JW
Rheum Dis Clin North Am; 2017 Feb; 43(1):27-41. PubMed ID: 27890172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
